Amgen, a leading biotechnology company, was founded on April 8, 1980, by Dr. George B. Rathmann and Dr. Joseph Rubinfeld. The company's inception can be traced back to the vision of Dr. Rathmann, a highly respected scientist and entrepreneur
, who recognized the potential of using genetic engineering techniques to develop innovative therapeutics. Dr. Rubinfeld, a renowned biochemist, joined forces with Dr. Rathmann to bring this vision to fruition.
The story of Amgen's founding begins with Dr. Rathmann's desire to create a company that would focus on developing novel therapeutics using recombinant DNA technology. This technology, which allows for the manipulation and expression of genes in organisms, held immense promise for the field of medicine. Dr. Rathmann believed that by harnessing this technology, it would be possible to produce therapeutic proteins that could address unmet medical needs.
To transform this vision into reality, Dr. Rathmann sought out a partner who shared his passion for scientific innovation and entrepreneurship. He found this partner in Dr. Rubinfeld, who had extensive experience in the biotechnology industry and a deep understanding of the potential of genetic engineering. Together, they embarked on a journey to establish a company that would pioneer the development of groundbreaking biologic medicines.
On that fateful day in April 1980, Amgen was officially incorporated in Thousand Oaks, California. The name "Amgen" is derived from the company's original name, Applied Molecular Genetics Inc., which reflected its focus on applying molecular biology techniques to the development of therapeutics.
From its humble beginnings, Amgen quickly gained recognition for its pioneering work in the field of biotechnology. The company's first major breakthrough came in 1983 when it successfully produced a recombinant version of erythropoietin (EPO), a hormone responsible for red blood cell production. This achievement marked a significant milestone in the treatment of anemia and laid the foundation for Amgen's future success.
Over the years, Amgen continued to innovate and expand its portfolio of therapeutics. The company developed several groundbreaking drugs, including Neupogen® (filgrastim) and Epogen® (epoetin alfa), which revolutionized the treatment of cancer-related infections and anemia, respectively. These achievements propelled Amgen to the forefront of the biotechnology industry and solidified its reputation as a leader in biologic medicines.
Today, Amgen stands as one of the largest biotechnology companies in the world, with a diverse pipeline of innovative therapies addressing a wide range of diseases. The company's commitment to scientific excellence, patient-centricity, and continuous innovation has enabled it to make significant contributions to the field of biotechnology and improve the lives of countless patients worldwide.